Circulating Biomarkers of immune activation distinguish viral suppression from nonsuppresion in HAART-treated patients with advance HIV-1 sub type C infection
Despite the undoubted success of highly-active anti-retroviral therapy (HAART), residual, lowgrade, chronic immune activation is sustained for several years, even in the setting of effective viral suppression, with an accompanying increased risk for development of inflammation-associated degenerative disorders and cancer. Notwithstanding the possible involvement of viral reservoirs, the chronic escape of pro-inflammatory microbial products from a damaged gastrointestinal tract into the portal and systemic circulation is believed to underpin this state of immune activation. The recent study reported by Malherbe et al. in “Mediators of Inflammation” describes the alterations in the concentrations of a range of circulating pro-inflammatory/anti-inflammatory biomarkers, representative of various immune and inflammatory cell types, in a cohort of patients infected with HIV subtype C, prior to and at 6 months after initiation of HAART, as well as in second cohort with proven treatment failure.
Learn more / download: [PDF]